296 related articles for article (PubMed ID: 19218271)
21. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
22. A Narrative Review of the Impact of Extracorporeal Membrane Oxygenation on the Pharmacokinetics and Pharmacodynamics of Critical Care Therapies.
Patel JS; Kooda K; Igneri LA
Ann Pharmacother; 2023 Jun; 57(6):706-726. PubMed ID: 36250355
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration.
Fuhrmann V; Schenk P; Jaeger W; Miksits M; Kneidinger N; Warszawska J; Holzinger U; Kitzberger R; Thalhammer F
J Antimicrob Chemother; 2007 Nov; 60(5):1085-90. PubMed ID: 17855725
[TBL] [Abstract][Full Text] [Related]
24. The calcineurin inhibitor cyclosporin A exhibits synergism with antifungals against Candida parapsilosis species complex.
Cordeiro RA; Macedo RB; Teixeira CEC; Marques FJF; Bandeira TJPG; Moreira JLB; Brilhante RSN; Rocha MFG; Sidrim JJC
J Med Microbiol; 2014 Jul; 63(Pt 7):936-944. PubMed ID: 24722799
[TBL] [Abstract][Full Text] [Related]
25. Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation.
Zhao Y; Seelhammer TG; Barreto EF; Wilson JW
Pharmacotherapy; 2020 Jan; 40(1):89-95. PubMed ID: 31742741
[TBL] [Abstract][Full Text] [Related]
26. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.
Crandon JL; Banevicius MA; Fang AF; Crownover PH; Knauft RF; Pope JS; Russomanno JH; Shore E; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2009 Dec; 53(12):5102-7. PubMed ID: 19770284
[TBL] [Abstract][Full Text] [Related]
27. The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient.
Quintard H; Papy E; Massias L; Lasocki S; Arnaud P; Desmonts JM; Montravers P
Ther Drug Monit; 2008 Feb; 30(1):117-9. PubMed ID: 18223474
[TBL] [Abstract][Full Text] [Related]
28. Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support.
Miller M; Kludjian G; Mohrien K; Morita K
Am J Health Syst Pharm; 2022 Jul; 79(15):1245-1249. PubMed ID: 35377411
[TBL] [Abstract][Full Text] [Related]
29. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.
Brüggemann RJ; Antonius T; Heijst Av; Hoogerbrugge PM; Burger DM; Warris A
Ther Drug Monit; 2008 Dec; 30(6):643-6. PubMed ID: 19057370
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
[TBL] [Abstract][Full Text] [Related]
32. Steady-state pharmacokinetics and metabolism of voriconazole in patients.
Geist MJ; Egerer G; Burhenne J; Riedel KD; Weiss J; Mikus G
J Antimicrob Chemother; 2013 Nov; 68(11):2592-9. PubMed ID: 23766489
[TBL] [Abstract][Full Text] [Related]
33. Voriconazole: review of a broad spectrum triazole antifungal agent.
Kofla G; Ruhnke M
Expert Opin Pharmacother; 2005 Jun; 6(7):1215-29. PubMed ID: 15957974
[TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
35. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
Keirns J; Sawamoto T; Holum M; Buell D; Wisemandle W; Alak A
Antimicrob Agents Chemother; 2007 Feb; 51(2):787-90. PubMed ID: 17116670
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses.
Colitz CM; Latimer FG; Cheng H; Chan KK; Reed SM; Pennick GJ
Am J Vet Res; 2007 Oct; 68(10):1115-21. PubMed ID: 17916020
[TBL] [Abstract][Full Text] [Related]
37. A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation.
Van Daele R; Bekkers B; Lindfors M; Broman LM; Schauwvlieghe A; Rijnders B; Hunfeld NGM; Juffermans NP; Taccone FS; Coimbra Sousa CA; Jacquet LM; Laterre PF; Nulens E; Grootaert V; Lyster H; Reed A; Patel B; Meersseman P; Debaveye Y; Wauters J; Vandenbriele C; Spriet I
Microorganisms; 2021 Jul; 9(7):. PubMed ID: 34361978
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation.
Shekar K; Fraser JF; Smith MT; Roberts JA
J Crit Care; 2012 Dec; 27(6):741.e9-18. PubMed ID: 22520488
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulatory effects of voriconazole and caspofungin on human peripheral blood mononuclear cells stimulated by Candida albicans and Candida krusei.
Fidan I; Yesilyurt E; Kalkanci A; Aslan SO; Sahin N; Ogan MC; Dizbay M
Am J Med Sci; 2014 Sep; 348(3):219-23. PubMed ID: 24662309
[TBL] [Abstract][Full Text] [Related]
40. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
